PoliticalRepoPoliticalRepo

United States · Law · S

S. 164 (117th)

Advancing Education on Biosimilars Act of 2021

enactedUnited States· United States Congress· EN

Introduced

2 February 2021

Last action

—

Status

Became Public Law No: 117-8.

Sponsors

—

Subjects

Discovery layer

Source updated

22 December 2025

Official sourceDownload fileView documentsShare

Summary

Advancing Education on Biosimilars Act of 2021 This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.) The FDA may also maintain and operate a website to provide educational materials about biological products.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

12 official files

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.